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Objective: Metabolic abnormalities are common long-
term side effects of antiretroviral treatment. In this
study we investigated the prevalence of dyslipidemia and
metabolic abnormalities in 2 groups of HIV-infected patients
receiving highly active antiretroviral therapy (HAART) and
antiretroviral-naive patients.
Methods: 40 HIV infected patients treated by HAART as a
case group and 15 HIV naive, as a control group enrolled in
this study. The two groups were well balanced with respect
to age, sex, CD4 cell counts.
Results: Levels of total cholesterol, triglycerides, and
lactate were elevated in 24%, 37%, and 25% of patients,
respectively. The prevalence of elevated triglyceride and
cholesterol levels was signiﬁcantly higher among patients
receiving antiretroviral therapy than it was among those
who were not receiving treatment. Fasting hyperglycemia
was noted in 11% of patients overall, but this was not signif-
icantly associated with antiretroviral treatment group. Low
HDL levels were noted in 44.4% of patients overall, and this
ﬁnding did not vary by treatment group. We found signiﬁ-
cant difference regarding mean of total cholesterol and LDL
between treated group and controls (P < 0.05).No signiﬁcant
difference was observed in mean of HDL, Lactate and fasting
blood sugar levels between each treated group and controls.
Conclusion: We concluded that in HIV infected patients
with exposure to HAART, hyperlipidemia was a common
metabolic complication. The prevalence of metabolic abnor-
malities in Iranian HIV-infected patients was similar to those
reported for Western and Asian studies.
doi:10.1016/j.ijid.2008.05.496
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Background: Gynecomastia (G) is an emerging untoward
event in patients treated with HAART.
Patients and Methods: Through a cross-sectional study
performed on around 1,000 HIV-infected patients (p) treated
with antiretrovirals at our reference centre in Bologna
(Italy),we identiﬁed all cases of G related to the admin-
istration of at least 12 consecutive months of HAART,to
assess possible correlations of G with a spectrum of clini-
cal,laboratory,and therapeutic variables (and including all
adverse effects of HAART itself). All p with true G (as distin-
guished from lipomastia by an ultrasonography assay) were
considered evaluable,while p with other predisposing con-
ditions (endocrine disease,alcohol abuse,liver cirrhosis,and
use of drug possibly predisposing to G), were carefully
excluded.
Results: Twenty-one out of 616 evaluable HIV-infected
male p (3.4% of our p population), developed a true G
when aged 12—58 years. Seven p out of 21 never received
protease inhibitor (PI)-containing therapies,while efavirenz-
based regimens apparently prompted G in seven p who were
na¨ıve for PI,and worsened this disturbance in three further p
who abandoned PI for efavirenz.Considering nucleoside ana-
logues (NA), two p developed G during treatment conducted
with dual isolated NA. Comparing the different administered
NA,stavudine seemed to be the most commonly used com-
pound, also taken for the longest time (p < .01).A complete
hormonal workup did not detect signiﬁcant abnormalities,
save in one p, who had slight serum FSH,LH,and testos-
teron abnormalities (with normal prolactin levels).When
considering the eventual correlation with the most common
HAART-induced disturbances,some forms of lipodystrophy
was concurrent in all the 21 p with G,while hypertriglyc-
eridemia,hypercholesterolemia,and hyperglycemia were
found in 15,9,and three p, respectively. During the subse-
quent 12—36-month follow-up, a spontaneous ameliorement
of G was never observed,notwithstanding eventual HAART
modiﬁcations.Due to local hypersthesia,tenderness,and dis-
comfort,two p resorted to surgery.
Conclusions: G is probably an underestimated problem
in the setting of HAART.The frequent association of G with
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Background: Higher incidences of symptomatic hyperlac-
tatemia (SHL) and lactic acidosis (LA) have been reported
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in South Africa where dideoxynucleosides are used as nucle-
oside backbones for HAART in the public sector. This study
reviews the incidence, characteristics, analysis frequently
reported symptoms and documents outcomes of SHL and LA.
Method: Retrospective cohort analysis was performed
of 1175 adults (66.5% female) who started on ART from
January 2004 to January 2007 at the Tygerberg Hospital
Infectious Diseases Clinic. All patients with two lactate lev-
els of >2,5mmol/l and symptoms compatible with SHL during
the study period were included in the analysis.
Results: A total of 79 patients presented with SHL (65
female). The overall incidence was 42 cases per 1000
patient- years. The incidence among female patients was
36.1 cases per 1000 p-y compared to 6.1 cases per 1000 p-y
on treatment among male patients. 46 patients (58%) had
lactate measurements of >5mmol/l giving it and incidence
of 22 cases per 1000 p-y. Two patients (2, 5%) died. Median
age was 37 years, median baseline CD4 102 and median dura-
tion of ART was 11 months. The baseline median BMI was 24,
1. Seventeen (23, 6%) of 72 patients with SHL were obese
(BMI > 30). All 79 patients were on d4T prior to develop-
ing SHL. Most frequently reported symptoms were weight
loss (61%), nausea and vomiting 58%, abdominal pain or ten-
derness 55% and peripheral neuropathy occurred in 51% of
patients. Of the 70 patients restarted or continued with AZT
only 1 patient developed a recurrence.
Conclusion: A higher incidence was found as the cohort
included the entire spectrum of SHL. The frequency of SHL
was higher among women. The low mortality in this cohort
is likely due to increased awareness of clinicians and due
to inclusion of mild to moderate forms of SHL. AZT seems
a safe alternative where NRTI options are limited. These
ﬁndings mirror results found in other South African cohort
in the public sector ARV roll-out program.
doi:10.1016/j.ijid.2008.05.498
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The Government of Tanzania launched ARV programme
for PLHA since 2003, with the aim of decrease suppression
of HIV replication, improve patient’s survival and to reduce
morbidity. At Ligula hospital in Mtwara Municipal where this
study was conducted, the programme was introduced in
June 2005. This dissertation attempts to describe a study
conducted to identify the factors contributing to ARV non-
adherence among PLHA attending CTC at Ligula hospital.
This study was under taken during October 2006 with 50
respondents who included 45 ARV users and ﬁve (5) service
providers. The respondents were selected by using simple
random sampling method. Data was collected by using a
semi-structured questionnaire, and then data analysis was
done manually.
Majority (60%) of respondents reported to have had failed
to adhere to prescribed regimen. The reasons for non-
adherence included; 55% lack of privacy, 44.4% long distance
to hospital, 44.4% out of their home and 41% simply forgot
33.3% don’t want to be notice, 25% alternative therapy, 15%
side effect of drug. When reporting about non-adherence,
the interviewed service providers mentioned the use of tra-
ditional medicine 80%, low capacity of client to understand
80% economic constraints 60%, lack of support 40%, long
distance to clinic 20%, side effect 20%, and feels recovery
20%.
This study concludes that, factors for ARV’s non-
adherence are multi-factorial. These results are useful in
planning interventions to promote medication adherence
among clients receiving ARV at Ligula hospital and similar
settings. Both clients and providers should be targeted by
interventions aimed at improving adherence to ARVs.
doi:10.1016/j.ijid.2008.05.499
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Background: Due to limited regimen options in resource-
limited settings, it is important to maximize the durability of
response to ﬁrst-line antiretroviral therapy in order to opti-
mize patient outcomes and maintain lower program costs.
Objectives: To conduct a pilot study of initiation of a one-
month period of directly administered antiretroviral therapy
(DAART) for participants with suspected ﬁrst-line treatment
failure. The primary outcome was the change in CD4 lym-
phocyte count following DAART.
Methods: We conducted a prospective cohort study in
Mombasa, Kenya between 2004 and 2007. We identiﬁed all
women on ART who met WHO criteria for immunological
treatment failure but were clinically stable. These women
received four weeks of DAART, during which we directly
administered the morning dose at the clinic for ﬁve days
each week.
Results: Fourteen women resumed DAART. The median
time to suspected treatment failure was 428 days (interquar-
tile range [IQR], 333—819 days), and the median CD4 cell
count at treatment failure was 152 cells/microliter (IQR,
112—232). Following one month of DAART, 5 women were
diagnosed with treatment failure, while 9 women were
no longer classiﬁed as failing. Among those who failed,
the median CD4 counts were 153 cells/microliter (IQR, 63-
